Supira Medical Receives FDA Approval for SUPPORT II Study, Marks Breakthrough in Cardiogenic Shock Treatment Supira Medical has announced the FDA's approval for the SUPPORT II study, a major advancement in treating cardiogenic shock and the appointment of D. Keith Grossman to its board.

Supira Medical Receives FDA Approval for SUPPORT II Study, Marks Breakthrough in Cardiogenic Shock Treatment #USA #Los_Gatos #Supira_Medical #cardiogenic_shock #SUPPORT_II

Supira Medical Achieves FDA Approval for Critical SUPPORT II Trial, Enhancing Treatment Options Supira Medical, Inc. announces FDA approval for its SUPPORT II trial, a vital step in enhancing cardiogenic shock treatment options and appoints D. Keith Grossman to its board.

Supira Medical Achieves FDA Approval for Critical SUPPORT II Trial, Enhancing Treatment Options #USA #Los_Gatos #Supira_Medical #pVAD #cardiogenic_shock

New Study Confirms the Long-Term Benefits of the Impella CP Heart Pump in Cardiogenic Shock Patients Recent findings confirm that the Impella CP heart pump offers significant long-term survival benefits for patients with cardiogenic shock, as published in a leading medical journal.

New Study Confirms the Long-Term Benefits of the Impella CP Heart Pump in Cardiogenic Shock Patients #United_States #New_York #Johnson_&_Johnson #Impella_CP #cardiogenic_shock